Chronic respiratory management is currently undergoing a significant paradigm shift. Experts now advocate for global airway disease remission as a primary therapeutic target. Consequently, advanced disease-modifying therapies, such as biologics and allergen immunotherapy, are making this ambitious goal a reality for patients with severe asthma, allergic rhinitis (AR), and chronic rhinosinusitis with nasal polyps (CRSwNP).

The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) recently convened an international panel to standardize this approach. This consensus provides essential guidance for clinicians aiming to move beyond simple symptom control. Importantly, the panel emphasizes that remission is a therapeutic target independent of initial disease severity. Furthermore, the consensus suggests that clinicians should view comorbid conditions, such as allergic asthma and AR, as features of a single unified disease entity rather than separate comorbidities.

Inducing and Maintaining Global Airway Disease Remission

Clinical assessment requires specific parameters to confirm success in achieving a remission state. The expert panel recommends a minimal observation period of 12 months to formally define remission. During this timeframe, healthcare providers should utilize a 4-week recall window to accurately assess symptom control. Moreover, while multidisciplinary approaches are necessary, each subspecialty must evaluate the patient separately to ensure comprehensive care. Because clinical utility is vital, the consensus prioritizes pragmatic definitions that physicians can easily implement in daily practice.

Inducing remission often involves early intervention with targeted therapies that address underlying inflammatory pathways. However, maintaining this state requires consistent monitoring and a shift in long-term management strategies. This transition from a focus on control to a focus on global airway disease remission represents a major advancement in optimizing long-term patient outcomes and quality of life.

Frequently Asked Questions

What is the minimum period required to define disease remission?

The EUFOREA panel suggests a minimum period of 12 months of sustained symptom control and disease stability to formally define clinical remission in airway diseases.

Are remission goals only for patients with severe disease?

No, the consensus explicitly states that remission is a therapeutic target independent of disease severity and should be considered for patients across the disease spectrum, not just those with severe cases.

How should comorbidities like asthma and nasal polyps be viewed?

The consensus recommends treating these conditions as features of a single underlying airway disease rather than treating them as isolated comorbidities.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Virchow JC et al. Remission in Global Airway Diseases: EUFOREA Consensus Paper. Allergy. 2026 Jun 16. doi: 10.1111/all.70415. PMID: 42304188.

Hellings PW et al. Remission in chronic rhinosinusitis with nasal polyps (CRSwNP). Rhinology. 2025 Apr 1;63(2):239-241. doi: 10.4193/Rhin24.457.

Jesenak M et al. Promoting Prevention and Targeting Remission of Asthma: A EUFOREA Consensus Statement on Raising the Bar in Asthma Care. Allergy. 2025 Apr 15;80(4):956-974.